Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells 3,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider directly owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Monday, December 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00.
• On Monday, November 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00.

Gilead Sciences Stock Performance

Shares of GILD traded up $3.65 during trading hours on Friday, hitting $124.91. The company’s stock had a trading volume of 10,638,850 shares, compared to its average volume of 6,570,563. The business has a 50 day simple moving average of $123.24 and a two-hundred day simple moving average of $117.92. Gilead Sciences, Inc. has a 52-week low of $91.68 and a 52-week high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The company has a market cap of $154.97 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 0.65 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the company posted $2.02 EPS. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Trivium Point Advisory LLC grew its stake in Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after buying an additional 83 shares in the last quarter. Binnacle Investments Inc lifted its holdings in shares of Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC grew its position in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Hemington Wealth Management increased its stake in Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the last quarter. Finally, Ignite Planners LLC raised its position in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on GILD shares. HSBC increased their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. UBS Group reissued a “buy” rating on shares of Gilead Sciences in a report on Thursday. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Mizuho upped their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $133.16.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.